SCHEMBL8540758

SCHEMBL8540758

CS(=O)(=O)/C(C#N)=C\c1cccc([N+](=O)[O-])c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
HIF1A Q16665 1/20 0.58
ALDH1A1 P00352 6/20 0.55
KDM4E B2RXH2 5/20 0.55
KMT2A Q03164 3/20 0.55
LMNA P02545 3/20 0.55
GLO1 Q04760 2/20 0.55
MAPT P10636 4/20 0.53
RAB9A P51151 1/20 0.53
PPME1 Q9Y570 1/20 0.53
FBP1 P09467 2/20 0.52
MEN1 O00255 2/20 0.49
HSP90AA1 P07900 1/20 0.47
PKM P14618 1/20 0.47
CCR6 P51684 1/20 0.47
NFE2L2 Q16236 2/20 0.47
VCP P55072 1/20 0.46
CYP19A1 P11511 1/20 0.46
CA1 P00915 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8540762 1.00 CYP1A2 (0.58) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL11565020 0.84 CYP1A2 (0.65) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL29289251 0.83 ALDH1A1 (0.60) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL29289250 0.83 ALDH1A1 (0.60) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL11562290 0.82 ALDH1A1 (0.54) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL11560363 0.81 ALDH1A1 (0.53) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL11564787 0.80 CYP1A2 (0.49) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL4943479 0.80 CYP1A2 (0.63) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL29894113 0.80 CYP1A2 (0.63) CYP1A2CYP3A4HIF1AALDH1A1KDM4E
SCHEMBL4077804 0.77 EGFR (0.67) CYP1A2CYP3A4ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0537949-B1 Antiproliferative derivatives of 4H-naphtho 1,2-b pyran LILLY CO ELI (GB) 1998-07-01 EP disclosed
EP-0618206-B1 Pharmaceutical compounds LILLY INDUSTRIES LTD (GB) 1997-09-17 EP disclosed
US-5576325-A TREATMENT OF IMMUNE DISEASES, RESTENOSIS, ENZYME INHIBITORS AND ANTISPASMODIC AGENTS LILLY INDUSTRIES LIMITED (GB) 1996-11-19 US disclosed
US-5574034-A TREATMENT OF IMMUNE DISEASES AND EXCESS CELL PROLIFERATION, ENZYME INHIBITORS ELI LILLY AND COMPANY (US) 1996-11-12 US disclosed
US-5571818-A FOR TREATING IMMUNE DISEASES OR A DISEASE IN WHICH EXCESS CELL PROLIFERATION OR ENZYME RELEASE OCCUR ELI LILLY AND COMPANY (US) 1996-11-05 US disclosed
US-5514699-A Pharmaceutical compounds LILLY INDUSTRIES LIMITED (GB) 1996-05-07 US disclosed
EP-0618206-A1 Pharmaceutical compounds LILLY INDUSTRIES LIMITED (GB) 1994-10-05 EP disclosed
US-5284868-A Naphthopyran derivatives; for autoimmune diseases, cancer ELI LILLY AND COMPANY (US) 1994-02-08 US disclosed
US-5281619-A Administering naphtho(1,2-B)pyran derivatives ELI LILLY AND COMPANY (US) 1994-01-25 US disclosed
EP-0537949-A1 Antiproliferative derivatives of 4H-naphtho 1,2-b pyran LILLY INDUSTRIES LIMITED (GB) 1993-04-21 EP disclosed